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Abstract
Background: Osteosarcoma (OS) is a high-grade bone sarcoma with early metastasis potential, and the clinical
chemotherapy drugs that are currently used for its treatment have some limitations. Recently, several studies have
reported the selective antitumor effect of oleandrin on various tumor cells. In this study, we aimed to evaluate the
effects and underlying mechanisms of oleandrin on OS cells.
Methods: The effect of oleandrin on the proliferation, morphology, and apoptosis of U2OS and SaOS-2 cells were
analyzed in vitro. The activity of the Wnt/β-catenin signaling pathway was determined using a dual luciferase assay.
Semi-quantitative RT-PCR and western blot assays were performed to evaluate the mRNA and total protein expression
of the downstream target genes. Changes of β-catenin in intracellular localization were also explored using a western
blot after separating the nucleus and cytoplasm proteins. The MMP-2 and MMP-9 enzymatic activities were determined
using gelatin zymography.
Results: Oleandrin significantly inhibited the proliferation and invasion of OS cells in vitro, and induced their apoptosis.
After treatment with oleandrin, the TOP/FOP flash ratio in OS cells was noticeably decreased, which indicated that the
Wnt/β-catenin signaling pathway was repressed. The expression of related Wnt target genes and total β-catenin was
downregulated, and a reduced nuclear β-catenin level by oleandrin was observed as well. In addition, oleandrin
suppressed the activities of MMP-2 and MMP-9.
Conclusions: Oleandrin, in vitro, exerted a strong antitumor effect on human OS cells by suppressing the Wnt/β-catenin
signaling pathway, which interfered with the proliferation and invasion of OS cells, as well as induced cells apoptosis.
Moreover, the expression and activities of MMP-2 and MMP-9 were downregulated by oleandrin, which contributed to
the cells’ lower invasiveness.
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Background
Osteosarcoma (OS) is a high-grade malignant bone
tumor caused by genetic and epigenetic changes that
interrupt osteoblast differentiation from mesenchymal
stem cells with a high potential for local destruction and
distant metastasis [1, 2]. OS mainly emerges in regions
of active bone growth, such as the knee joint, lower
femur and upper tibia, with a high incidence in
adolescents. The treatment for OS, which combines sur-
gery with neoadjuvant and adjuvant chemotherapy, has
developed rapidly [3]. Although the use of multi-drug
chemotherapy has greatly increased the 5-year survival
rate of patients, approximately 30 % of patients experience
relapse or metastasis. Importantly, the 5-year survival rate
of OS patients with pulmonary metastasis is extremely
poor, at 10–20 % [4]. Moreover, a variety of problems also
exist with the current therapies, such as chemotherapy
tolerance and side effects. This context limits the applica-
tion of clinical chemotherapy drugs. Therefore, the
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identification a new drug with selective cytotoxicity to
tumor cells is urgently needed.
Cardiac glycosides, a type of traditional drug that is used
to treat cardiac insufficiency, were recently reported to
have an antitumor effect on many tumor cells including
breast cancer, lung cancer as well as leukemia [5–7].
Oleandrin is a polyphenolic cardiac glycoside derived from
the leaves of Nerium oleander, which has been found to
have anti-proliferative effects on tumor cells [5]. The
evidence indicates that oleandrin could be a perfect alterna-
tive substance due to its selective antitumor and chemora-
diation sensitization properties [8]. Moreover, oleandrin
recently underwent a Phase I clinical trial as a novel drug
for anticancer therapy in patients with refractory solid
tumors [9].
There are some reports about the antitumor mecha-
nisms of oleandrin. Cardiac glycosides, such as olean-
drin, are known to inhibit the Na+, K+-ATPase pump,
resulting in a consequent increase of calcium influx in
the heart muscle [10]. Previous studies reported that
oleandrin inhibited the proliferation and induced the
apoptosis of cells due to an increase in intracellular Ca2+
via the inhibition of Na+, K+-ATPase [11]. Oleandrin
inhibited the export of fibroblast growth factor-2
through membrane interactions and Na+, K+-ATPase
activity in prostate cancer cells [12]. Oleandrin also
induced apoptosis in human leukemia cells through the
dephosphorylation of Akt and expression of Fas L, as
well as by altering the membrane fluidity [8]. In addition,
it suppressed the activation of NF-kB and induced Fas
expression and autophagosome formation in tumor cells.
The inhibition of Akt phosphorylation and the increase
of MAPK expression were also demonstrated in response
to oleandrin. The results of these studies have indicated an
impending injury and the death of tumor cells following
oleandrin treatment. However, no studies have described
the antineoplastic activity of oleandrin on osteosarcoma
cells and the related mechanisms.
Recent studies have reported the important effect of
the Wnt/β-catenin signaling pathway in tumorigenesis,
bone development and stem cell biology [13, 14]. Add-
itionally, the role of Wnt/β-catenin signaling pathway in
the occurrence of osteosarcoma has also been brought
to the forefront. The Wnt/β-catenin pathway is activated
when a Wnt ligand binds to its coreceptor complex, which
contains a Frizzled family member and low-density lipo-
protein receptor-related protein 5/6 (LRP-5/6). Subse-
quently, disheveled (Dsh) is activated and transmits
signals from the receptor to the APC/axin/GSK3 de-
struction complex to suppress the phosphorylation of
β-catenin by GSK-3β [15, 16]. Thus, unphosphorylated
β-catenin accumulates in the cytoplasm and translo-
cates into the nucleus, interacts with the T-cell factor/
lymphocyte enhancer factor (TCF/LEF) family of
transcription factors and activates downstream target
genes, including c-myc, cyclin D1, survivin and matrix
metalloproteinase (MMPs), which regulate cell cycle
and apoptosis, as well as metastasis [17].
In this study, we aimed to evaluate the effect of olean-
drin on OS cell lines in vitro and to investigate the
underlying mechanism involved in this process.
Methods
Cell lines and culture
U2OS and SaOS-2 cell lines, derived from the China
Infrastructure of Cell Line Resources (Chinese Academy
of Medical Sciences, Beijing, China), were cultured in
McCoy’s 5A (HyClone Laboratories of Thermo Scien-
tific, Logan, UT, USA) and Dulbecco’s modified eagle
medium (DMEM, HyClone Laboratories of Thermo
Scientific, Logan, UT, USA), respectively, which were
supplemented with 10 % fetal bovine serum (FBS,
HyClone Laboratories of Thermo Scientific, Logan, UT,
USA), 100 units/ml penicillin and 100 μg/ml strepto-
mycin (Gibco, Life Technologies, Inc., Grand Island,
NY) in a humidified incubator containing 5 % CO2 at
37 °C. Oleandrin was purchased from Sigma-Aldrich
Chemical Co. (St. Louis, CA, USA), and the purity was
approximately 99 %, as analyzed by HPLC. It was dis-
solved in 100 % dimethyl sulfoxide (DMSO, Sigma-
Aldrich Chemical Co., St. Louis, CA, USA) and diluted
with medium. As a vehicle control, cultured cells were
incubated in medium containing DMSO at a final con-
centration of less than 0.1 %.
Cell counting kit-8 (CCK-8) proliferation assay
U2OS or SaOS-2 cells were seeded in a 96-well dish at a
final density of 5 × 103 (U2OS) or 1 × 104 (SaOS-2) cells/
well and were incubated for 24 h. The cells were then
treated with oleandrin at increasing concentrations (25,
50, 75, and 100 nM) and the control medium for 24, 48
and 72 h. Thereafter, 10 μl CCK-8 (Dojindo Laborator-
ies, Kumamoto, Japan) was added to each well and incu-
bated for another 3 h. The absorption at 450 nm was
determined for each sample using an automatic ELISA
plate reader. Five replicate wells were used for each
treatment, and the experiments were repeated three
times. Cell viability (%) = [OD (treatment)-OD (blank)]/
[OD (control)-OD (blank)] × 100 %.
Colony formation assay
U2OS and SaOS-2 cells were seeded into 12-well plates
at a density of 100 cells/well. After adherence at 37 °C in
a 5 % CO2 humidified oven for 24 h, the cells were
treated with 25 nM and 50 nM oleandrin and the con-
trol medium at 37 °C for 10 days, during which the
medium containing the corresponding concentrations of
oleandrin was refreshed every 2 days. Ten days later, the
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colonies were fixed with 4 % paraformaldehyde and
stained with 0.5 % crystal violet. The number of colonies
in each well was counted under an inverted microscope
(Leica, Frankfurt, Germany).
DAPI staining
U2OS and SaOS-2 cells were seeded in 24-well plates
and treated with the control or 25 and 50 nM oleandrin
for 24 h. The cells were rinsed three times with PBS,
and Triton X-100 was added to break the cell membrane
integrity for 15 min. Then, DAPI (Beyotime, Shanghai,
China) was added for another 10 min of incubation in the
dark. The cell nuclei were observed and photographed at
400× magnification under a fluorescence microscope
(Leica DM3000, Frankfurt, Germany).
Apoptosis analysis by flow cytometry (FCM)
U2OS and SaOS-2 cells were seeded into 6-well plates
and adhered overnight. When a confluence of 70–80 %
was reached, both cell lines were exposed to 50 nM of
oleandrin for 0, 24 and 48 h. Subsequently, the cells
were collected and re-suspended in 500 μl of 1× binding
buffer. Five microliters of annexin V-FITC and 5 μl of
propidium iodide (PI) were added to all of the samples,
which were then incubated at room temperature for
5 min in the dark according to the manufacturer’s proto-
col from the Annexin V-FITC apoptosis detection kit
(BioVision Co, California, USA). The fluorescence inten-
sity of the cells was immediately analyzed by flow
cytometry.
Wound-healing assay
U2OS and SaOS-2 cells were seeded in a 6-well plate
and incubated for 24 h. A pipette tip was used to scratch
three perpendicular wounds into a cross shape, and the
wells were washed twice with PBS to remove the
detached cells. U2OS and SaOS-2 cells were treated with
25 nM oleandrin for a corresponding amount of time.
Oleandrin were diluted with medium containing 2 %
FBS to eliminate the influence of cell proliferation. The
wounds were photographed at each time point using an
inverted microscope (Leica). The distance migrated was
calculated by dividing the distance at the time point by
the distance at the beginning. For each experiment, a
total of 5 wounds were measured per group, and the
results were analyzed using Image J Software.
Transwell invasion assay
U2OS and SaOS-2 cells were starved in serum-free
medium for 24 h and then re-suspended in serum-free
medium with 25 nM oleandrin and the control medium.
Then, 5 × 104 cells per well were added to the upper
chamber pre-coated with Matrigel (diluted 4-fold with
PBS, BD Biosciences, Franklin Lakes, NJ), while the
lower chamber was filled with 500 μl of complete culture
medium containing 10 % FBS as a chemo-attractant
source. After 24 h of incubation at 37 °C, the cells that
had invaded the lower surface of the membrane were
fixed with 75 % ethanol and stained with crystal violet.
Using light microscopy, 5 random fields were selected,
and the cells in each field were counted under high mag-
nification (200×).
Gelatin zymography assay
U2OS cells were seeded in 6-well plates and incubated
with 1 ml of McCoy’s 5A medium containing oleandrin
for 24 h after adherence. Then, the supernatant was
collected and the protein concentration was determined
using the BCA Protein Assay Kit (Applygen Technologies
Inc., Beijing, China) according to the manufacturer’s
protocol. All samples were diluted in 2 × SDS-PAGE non-
reducing buffer (4 % SDS, 100 mM Tris–HCl pH6.8, 20 %
glycerol and 0.02 % bromophenol blue), and the mixtures
were separated on a SDS-PAGE gel (10 % separation gel
containing gelatin). The following processes were per-
formed according to the protocol from the MMP Zymo-
graphy Assay Kit (Applygen Technologies Inc., Beijing,
China). The gel was scanned by a gel documentation
system (Bio-Rad Co., Nanjing, China).
Semi-quantitative reverse transcription polymerase chain
reaction (RT-PCR)
For PCR analysis, U2OS cells were treated with 50 nM
oleandrin for 0, 24 and 48 h. Total RNA was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s protocol. Ten micrograms of
RNA were reverse transcribed into cDNA using GoScript™
Reverse Transcription System (Promega, Southampton,
UK). The cDNA was added to a 2 × Taq PCR MasterMix
(Tiangen Biotech Co., LTD, Beijing, China) containing
10 pmol/L of each of the corresponding primer pairs. The
detailed information of the primers used in this analysis
was listed in Table 1. PCR amplification was performed
with corresponding cycles of 94 °C for 3 min, 94 °C for
30 s, at the annealing temperature for 30 s, 72 °C for
1 min and 72 °C for 5 min. The PCR products were
separated on 1 % agarose gels and were stained with
ethidium bromide. The gels were scanned under a gel
documentation system (Bio-Rad Co.). β-actin was
used as an internal reference to verify equal concen-
trations of cDNA in each sample.
Western blot analysis
For protein expression analysis, U2OS cells were seeded
in 100-mm dishes and treated with 50 nM oleandrin for
0, 24 and 48 h. Total proteins were extracted by RIPA
lysis buffer (Applygen Technologies Inc., Beijing, China).
Cell nuclear and cytoplasm proteins were extracted
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separately using the NE-PER™ Nuclear and Cytoplasm
Extraction Reagents (Pierce Biotechnology Inc., Rockfold,
USA) according to the manufacturer’s protocol. The pro-
tein concentration was detected using the BCA method.
All the samples were mixed with 5 × sodium dodecyl sul-
fate (SDS) loading buffer (1:4), boiled for 5 min and stored
at −80 °C for later use. The same amount of protein was
separated on a discontinuous SDS-PAGE gel (8–15 % sep-
aration gel) and transferred to a nitrocellulose membrane
after electrophoresis. The membranes were blocked with
5 % BSA in TBS containing 0.05 % Tween 20 for 2 h and
were incubated with corresponding rabbit primary anti-
bodies overnight at 4 °C. The antibodies included β-
catenin (1:1000, Santa Cruz Biotechnology, USA), cyc-
lin D1, survivin, c-myc (1:1000, Cell Signaling Technol-
ogy, Boston, Massachusetts, USA), MMP-9, lamin A/C,
α-tubulin (1:1000, Abcam, Cambridge, MA, USA) and
GAPDH (1:2000, Tiangen Biotech Co., LTD, Beijing,
China). Among them, lamin A/C and α-tubulin were
used as internal controls for the nuclear and cytoplasm
proteins, respectively. GAPDH were used as an internal
control for the total protein. The secondary antibody was
an IRDye 800CW conjugated goat (polyclonal) anti-rabbit
IgG secondary antibody (1:10000, LI-COR, Nebraska,
USA). The fluorescent bands were visualized with an
Odyssey infrared imaging system (LI-COR), and the gray
values were analyzed using Odyssey V3.0 software.
Dual luciferase assay
The dual luciferase assay was performed with the dual-
luciferase®reporter assay system (Promega Corp., Madison,
WI). All reagents were prepared as described by the
manufacturer of the TCF Reporter Plasmid Kit (Millipore
Corp., MA, USA). After the transfection complex was
formed with FOP DNA, pRL-TK Vector renilla (Promega
Corp., Madison, WI) and 50 μl of DNA Lipofectamine™
2000 (Invitrogen, Carlsbad, CA), the cells were seeded into
96-well plates with 100 μl/well. U2OS cells were divided
into four groups: oleandrin (time): 50 nM oleandrin for 0,
24 and 48 h; oleandrin (concentration): 0, 25 and 50 nM
oleandrin for 24 h, LiCl + oleandrin (time) and LiCl +
oleandrin (concentration). For the LiCl groups, the cells
were pretreated with 20 mM LiCl for 6 h to activate the
Wnt signaling pathway. After the cells were lysed with
PLB for 15 min, firefly luciferase reagent LARII (100 μl)
and Stop & Glo Reagent (100 μl) (Promega Corp., Madison,
WI) were added. The OD values of the TOP flash and the
FOP flash were detected and the TOP/FOP ratio reflected
the activity of the Wnt/β-catenin signaling pathway.
Statistical analysis
The data were presented as the means ± standard devi-
ation (SD) and were analyzed with PASW statistics 18
software. A value of P < 0.05 was considered statistically
significant. Comparisons of two or more data sets were
analyzed using one-way analysis of variance (ANOVA),
and data with more than two variables were analyzed
using two-way repeated-measures ANOVAs with post
hoc Tukey’s analysis.
Results
The viability and proliferation of OS cells were
suppressed by oleandrin
The CCK-8 assay was performed to evaluate the anti-
proliferative effect of oleandrin on U2OS and SaOS-2 cells.
Using various concentrations of oleandrin to treat cells for
different times, both cell lines exhibited significantly differ-
ent viabilities with a decreasing trend of concentration- and
time- dependency (1a, b). For U2OS, the administration of
25 nM oleandrin decreased the cell viability without a sig-
nificant difference at 24 h (P > 0.05), but with a significant
difference at 48 h (P < 0.01). However, the viability of cells
was reduced significantly after treatment with 50 nM olean-
drin for 24 h (P < 0.01) and 48 h (P < 0.01). Subsequently,
Table 1 The details of primers in semi-quantitative RT-PCR
Gene Primer sequence (5’ to 3’) Annealing temperature (°C) Cycle number
c-Myc F: CCACACATCAGCACAACTACG 57 30
R: CCGCAACAAGTCCTCTTCAG
cyclin D1 F: TCGGGAGAGGATTAGGTTCC 57 30
R: GTCACTGGATGGTTTGTTGG
survivin F: GTCCCTGGCTCCTCTACTGTT 57 30
R: GATGTGAAGGTTGGGCTGAC
MMP-2 F: GACCACAGCCAACTACGATG 59 30
R: CACAGTCCGCCAAATGAAC
MMP-9 F: CATCGTCATCCAGTTTGGTGT 57 32
R: AGGGTTTCCCATCAGCATT
β-actin F: AGCGAGCATCCCCCAAAGTT 59 25
R: GGGCACGAAGGCTCATCATT
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only a few cells remained at 72 h post-treatment. For
SaOS-2, however, both 25 nM and 50 nM oleandrin signifi-
cantly decreased cell viability after treatment for 24 h (P <
0.01) and 48 h (P < 0.01). Based on these results, we se-
lected 25 nM or 50 nM oleandrin to treat the cells
for 24 h and 50 nM oleandrin to treat cells for 24 h
or 48 h in the following experiments.
The influence of oleandrin on the colony forming
abilities of OS cells was also observed by performing plate
clone formation assays. Both U2OS and SaOS-2 cells were
isolated separately and cloned as described in the Methods
section. After treatment with 25 nM and 50 nM oleandrin
for 24 h, the U2OS and SaOS-2 colonies were significantly
reduced (Fig. 1c). The cloning efficiencies of U2OS at 25
nM and 50 nM compared with the control were 24.0 %
and 1.5 % vs. 39.8 % (25 nM or 50 nM vs. control: P =
0.207 or P = 0.002; 25 nM vs. 50 nM: P = 0.019), respect-
ively (Fig. 1d). Correspondingly, the cloning efficiencies of
SaOS-2 at 25 nM and 50 nM compared with the control
were 41.5 % and 17.5 % vs. 69.0 % (25 nM or 50 nM vs.
control: P = 0.005 or P = 0.000; 25 nM vs. 50 nM: P =
0.011), respectively (Fig. 1d).
The morphology of OS cells was changed by oleandrin
treatment
After treatment with 25 nM and 50 nM oleandrin for 24 h,
U2OS and SaOS-2 cells were observed by an optical micro-
scope at a low magnification (50×) to a high magnification
(100× and 200×). After exposure to oleandrin, the number
of U2OS and SaOS-2 cells gradually reduced at low
magnification. At high magnification, we also observed that
both cell lines presented typical apoptotic morphological
changes, which included the irregularities in the cell sur-
faces and the vesicles in the cytoplasm after exposure to 25
nM and 50 nM oleandrin (Fig. 2a, b).
Oleandrin induced OS cells apoptosis
Dye 4’-6-diamidino-2-phenylindole (DAPI) staining is a clas-
sic method to reflect the morphological changes of the cell
nucleus in apoptosis. Fig. 2c shows that without oleandrin,
the cell nuclei of U2OS and SaOS-2 cells are dispersed uni-
formly. However, after exposure to the drug, many OS cell
nuclei became pyknotic and underwent karorrhexis and
karyolysis.
Next, we detected FCM apoptosis following Annexin V-
FITC and PI double staining to confirm this phenomenon.
After treatment with 50 nM of oleandrin, the total number
of apoptosed cells in both the U2OS and SaOS-2 cell lines
increased significantly (Fig. 3a, b). The apoptosis rates of
U2OS cells at 0, 24 and 48 h were 15.8 %, 29.0 % and
46.0 %, respectively (24 or 48 vs. 0 h: P = 0.005 or P
= 0.000; 24 vs. 48 h: P = 0.001) (Fig. 3c). Similarly, the
apoptosis rates of the SaOS-2 cells were 10.6 %, 22.2 %
and 31.8 %, respectively (24 or 48 vs. 0 h: P = 0.007 or P =
0.000; 24 vs. 48 h: P = 0.015) (Fig. 3d).
Oleandrin suppressed the migration and invasion of
U2OS and SaOS-2 cells
Given the cytotoxic activity of oleandrin at high concen-
trations, we used a low concentration (25 nM) to evaluate
Fig. 1 The inhibiting effect of oleandrin on OS cell proliferation. a/b The viability of U2OS (a) and SaOS-2 (b) cells after treatment with various
concentrations of oleandrin for varying times. c A macrograph of the clone formation of the U2OS and SaOS-2 cells. d Cloning efficiency (%) of
U2OS and SaOS-2 cells. n = 3. Mean ± SD. **P < 0.01, vs. control group (CTL). #P < 0.05, vs. 25 nM
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the effect of oleandrin on cell migration and invasion in
vitro with wound healing and transwell invasion assays, re-
spectively. In our pre-experiments, the migration rate of
U2OS was greater than that of SaOS-2, and after treatment
with oleandrin for nearly 48 h, the scratches in the control
of the U2OS cell line had already closed while the scratches
in the control of the SaOS-2 cell line had not (data not
shown). Therefore, we selected the treatment length for
U2OS to be 6, 12 and 24 h and the treatment length for
SaOS-2 to be 24, 48 and 72 h. The results showed that with
an increased treatment time, the migration capabilities of
both cell lines were suppressed (Fig. 4a, b). The ratio of the
distance migrated in the control group compared with the
25 nM oleandrin group in U2OS cells at 6, 12 and 24 h was
16.6 % vs. 12.6 % (P = 0.482), 28.2 % vs. 22.4 % (P = 0.213)
and 39.3 % vs. 17.1 % (P = 0.003), respectively (Fig. 4c).
Meanwhile, in the SaOS-2 cells, the corresponding results
at 24, 48 and 72 h were 31.4 % vs. 18.5 % (P = 0.023), 43.8
% vs. 21.9 % (P = 0.000) and 54.7 % vs. 24.8 % (P = 0.000),
respectively (Fig. 4d).
Consistent with the wound healing assay, the results of
the transwell invasion assay indicated that OS cells that
invaded from the Matrigel into the substratum of the
membrane were significantly decreased after treatment
(Fig. 4e). The numbers in the substratum of the mem-
brane per view under high magnification (200×) in the
control group compared with the 25 nM oleandrin group
of U2OS cells were 41.1 ± 5.7 vs. 25.8 ± 6.1 (P = 0.033),
and the corresponding numbers of SaOS-2 cells were
65.8 ± 12.3 vs. 39.4 ± 10.0 (P = 0.045) (Fig. 4f).
Oleandrin suppressed the activity of Wnt/β-catenin
signaling pathway
Previous studies reported that the abnormal activation
of the Wnt signaling pathway plays an important role in
OS pathogenesis. In this study, we explored whether
Fig. 2 The changes of the cell morphologies and cell nuclei caused by increasing concentrations of oleandrin. (a/b) The morphology of U2OS
(a) and SaOS-2 (b) cells was observed with an optical microscope at 50×, 100× and 200× magnification. c Nuclei staining of U2OS and SaOS-2
cells was performed with DAPI and was photographed at 400× magnification (karyopyknosis: arrow pointing; karyorrhexis: arrowhead pointing)
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oleandrin had an effect on the Wnt/β-catenin signaling
pathway, and a dual-luciferase assay was used to evaluate
this effect in U2OS cells. Fig. 5a shows that without LiCl,
an inhibitor of GSK-3β, oleandrin was able to suppress the
activities of Wnt/β-catenin signaling by downregulating
the TOP/FOP flash ratio in a concentration-dependent
manner (25 nM or 50 nM vs. control: P = 0.017 or P =
0.001, 25 nM vs. 50 nM: P = 0.043). In addition, after pre-
treatment with LiCl, the TOP/FOP flash ratio first in-
creased but then declined in a concentration-dependent
manner after oleandrin treatment (25 nM or 50 nM vs.
control: P = 0.073 or P = 0.005, 25 nM vs. 50 nM: P =
0.070). Similarly, Fig. 5b also shows that oleandrin could
downregulate the TOP/FOP flash ratio in a time-dependent
manner with LiCl (24 or 48 h vs. 0 h: P = 0.004 or P =
0.000, 24 vs. 48 h: P = 0.005) or without LiCl (24 or 48 vs.
0 h: P = 0.017 or P = 0.002, 24 vs. 48 h: P = 0.120).
Oleandrin downregulated the target gene expression of
the Wnt/β-catenin pathway at both the mRNA and
protein levels
To study the effect of oleandrin on the Wnt/β-catenin
signaling pathway, we detected the mRNA and total
protein expression changes of the downstream target
genes, which included c-myc, survivin, cyclin D1, MMP-
2 and MMP-9, using semi-quantitative RT-PCR and
western blot assays. As we expected, the results of the
RT-PCR showed that oleandrin significantly downregu-
lated the mRNA levels of these genes to different degrees
dependent on treatment time (Fig. 5c, d). In accordance
with the RT-PCR results, after treatment with oleandrin for
24 and 48 h, the protein expression of the target genes was
reduced, which indicated that oleandrin had a remarkable
inhibiting effect on the downstream molecules of the Wnt/
β-catenin signaling pathway (Fig. 6a, b).
Oleandrin inhibited the protein expression of β-catenin
and reduced its nuclear localization
As a key transcriptional factor, the expression and
nuclear accumulation of β-catenin directly influenced
the activity of the Wnt signaling pathway and regulated
the transcription and expression of the target genes.
Therefore, we explored the regulating effect of oleandrin
on β-catenin by western blot analysis of the total cytoplas-
mic and nuclear protein extracts. As shown in Fig. 6c, d,
oleandrin treatment led to significantly decreased total
Fig. 3 The apoptosis analysis of U2OS and SaOS-2 cells by flow cytometry (FCM). a/b The total apoptotic rates of U2OS (a) and SaOS-2 (b) cells
after treatment with 50 nM oleandrin for 0, 24, and 48 h. c/d The quantitative results of the apoptosis analysis of U2OS (c) and SaOS-2 (d) cells.
n = 3. Mean ± SD. **P < 0.01 vs. 0 h. #P < 0.05, ##P < 0.01 vs. 24 h
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β-catenin levels over time. According to the nuclear
and cytoplasmic protein expression results, we found
that β-catenin was located in the cytoplasm as well as
in the nucleus of the control. Nevertheless, after treat-
ment with 50 nM of oleandrin, the β-catenin located in
nucleus was gradually decreased, and the difference
became very evident (P < 0.01) after 48 h of treatment.
There was a slight decreasing trend in the levels of
cytoplamic β-catenin, but no significant difference was
observed.
Effects of oleandrin on the MMP-2 and MMP-9 activities
of human OS cells
Gelatin zymography is a simple yet powerful method to
detect proteolytic enzymes that are capable of degrading
gelatin from various biological sources. It is particularly
useful for the assessment of two key members of the
matrix metalloproteinase family, MMP-2 and MMP-9
[18, 19]. We used this method to further explore the
change of MMP-2 and MMP-9 activities in U2OS cells.
With the treatment of 25 nM and 50 nM of oleandrin
for 24 h, the ability of MMP-2 and MMP-9 to degrade
gelatins was significantly reduced (Fig. 6e).
Discussion
Osteosarcoma is the most frequent malignant bone
tumor and is derived from primitive bone-forming mes-
enchymal cells with a high propensity for neovasculari-
zation and distant metastasis [20], which could seriously
threaten the patients’ life.
Recently, oleandrin has been used as a novel drug to
treat malignant tumors due to its selectively tumor-
killing and radio-chemotherapy sensitization effects.
Newman et al. [5] reported that oleandrin had a potent
Fig. 4 The changes of OS cell migration and invasion abilities after treatment with oleandrin. a/b The migration of U2OS and SaOS-2 cells before
and after treatment of U2OS cells (a, for 6, 12 and 24 h) and SaOS-2 cells (b, for 24, 48 and 72 h) with 25 nM oleandrin, was determined by a wound
healing assay. c/d A graphical representation of the average distance moved by U2OS (c) and SaOS-2 (d) cells in the oleandrin-treated and control
groups. e The invasiveness of U2OS and SaOS-2 cells was observed by a transwell invasion assay after treatment with 25 nM oleandrin for 24 h and
was compared to the control group. f The number of cells that invaded the substratum of the membrane per view under a 200× magnification. n = 3.
Mean ± SD. *P < 0.05, **P < 0.01, vs. control group (CTL)
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cytotoxicity to human melanoma cells and induced cells
apoptosis. Manna et al. [21] reported that oleandrin
could suppress the activation of nuclear transcription
factor-κB (NF-κB), activator protein-1 (AP-1), and c-Jun
NH2-terminal kinase. NF-κB and AP-1 are known to
play major roles in cell proliferation, tumor promotion,
and drug resistance [22]. Boulares et al. [23] also indi-
cated that oleandrin could activate NF-κB in different
cell types and induce apoptosis by caspase-dependent
PARP cleavage and DNA fragmentation. The study of
McConkey et al. [11] demonstrated that oleandrin treat-
ment led to the apoptosis of prostate tumor cells, and
this effect is mediated through the inhibition of Na+,
K+-ATPase. Moreover, Frese et al. [7] found that oleandrin
could enhance the pro-apoptotic sensibility of non-small
cell lung cancer, which is induced by Apo2L/TRAIL
through the upregulation of the death receptors 4 and 5.
In this study, we explored the effect of oleandrin on OS
cells and the related mechanisms.
First, the influence of oleandrin on the viability and pro-
liferation of OS cells were determined by CCK-8 and
clone formation assays. Our results showed that oleandrin
treatment reduced the viability of U2OS and SaOS-2 cells
in a time- and concentration-dependent manner and de-
creased the cell cloning efficiencies. Under a light micro-
scope, we also observed that following treatment with 25
nM and 50 nM of oleandrin for 24 h, the cell surfaces
were irregular and vesicles existed in the cytoplasm, which
are typical apoptotic morphological changes [24]. There-
fore, we concluded that oleandrin could inhibit the prolif-
eration of OS cells and induce their apoptosis, which was
also confirmed by DAPI staining and FCM. DAPI staining
showed that oleandrin treatment led to the nuclei of OS
cells presenting with pyknotic, karorrhexis and even kary-
olysis characteristics, while the cell nuclei in the control
group were uniformly dispersed. FCM also indicated that
the total apoptosis rates of both OS cells were increased
significantly with treatment time. All of these findings in-
dicate that oleandrin can dramatically induce OS cell
apoptosis, which is consistent with previous studies that
reported the apoptosis-induction effect of oleandrin on
other tumor cells [25]. Cell migration is a tightly regulated
process that occurs in tissue development and underlies
pathological conditions, such as cancer invasion, and cell
invasiveness, which is a crucial process of cancer metasta-
sis [26, 27]. We also observed the effect of oleandrin on
Fig. 5 Changes in the Wnt/β-catenin signaling activities of U2OS and the mRNA expression levels of related downstream genes in this pathway.
(a/b) With or without pretreatment with 20 μM LiCl, the TOP/FOP flash ratios were detected using a dual-luciferase assay in U2OS cells after treatment with
0, 25 and 50 nM of oleandrin for 24 h (a), or 50 nM of oleandrin for 0, 24 and 48 h (b), respectively. n= 3, Mean ± SD. *P< 0.05, **P< 0.01, compared to the
control group without LiCl in each intervention condition (0 nM group or 0 h group); #P< 0.05, ##P< 0.01, in the absence of LiCl, 25 nM group v.s. 50 nM
group, 24 h group vs. 48 h group; †P< 0.05, ‡P< 0.01, compared to the control group with LiCl in each intervention condition (0 nM group or 0 h group).
c The gel electrophoresis of c-myc, survivin, cyclin D1, MMP-2, MMP-9 and β-actin after amplification. d The semi-quantitative relationship between the
mRNA expression levels of related target genes and β-actin in U2OS cells according to the results of gel electrophoresis in RT-PCR after treatment with 50
nM of oleandrin for 0, 24 and 48 h. *P< 0.05, **P< 0.01, compared to the 0 h group. #P< 0.05, ##P< 0.01, compared to the 24 h group
Ma et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:115 Page 9 of 12
the migration and invasion of U2OS and SaOS-2 cell lines
by using a wound healing assay and a transwell invasion
assay. The results showed that the migration rates of both
cell lines were inhibited and that the number of OS cells
that moved from the Matrigel into the substratum of the
membrane was significantly decreased by oleandrin appli-
cation. These results support that oleandrin can not only
suppress the migration of OS cells but also inhibit their
invasion capacities.
Previous studies had reported that the activation of
the Wnt/β-catenin signaling pathway was widely appar-
ent in OS tissue/cells and that its aberrant activation
played a significant role in OS tumorigenesis, metastasis
and chemotherapeutic responses [28, 29]. In this study,
we explored whether oleandrin had an effect on the
Wnt/β-catenin signaling pathway, and the dual-luciferase
reporter assay with the TOP/FOP flash plasmid system
was used to evaluate this mechanism in U2OS cells. The
TOP/FOP flash plasmid system is the most common
method and has been used by many previous studies to
evaluate the transcriptional activity of TCF/LEF in
Wnt/β-catenin signaling [30]. In this study, we detected
the values of the TOP flash and the FOP flash of OS cells
under oleandrin treatment with or without LiCl, an
inhibitor of GSK-3β. Additionally, the TOP/FOP flash
ratio was presented to reflect the activity of Wnt/β-
catenin signaling. The results demonstrate that the TOP/
FOP flash ratio dramatically decreased in a time- and
concentration-dependent manner, which demonstrates that
the transcriptional activity of TCF/LEF was suppressed by
oleandrin. Even after the Wnt/β-catenin signaling in OS
cells was pre-activated by LiCl, the TOP/FOP flash ratio
still declined in a time- and concentration-dependent fash-
ion after exposure to oleandrin. Thus, we speculated that
oleandrin may suppress the activity of the Wnt/β-ca-
tenin signaling pathway and further influence the
downstream genes of this pathway, such as c-myc,
cyclin D1, survivin and matrix metalloproteinases
(MMPs) [31].
c-Myc is a helix-loop-helix leucine zipper phosphopro-
tein that regulates gene transcription in cell proliferation,
cell differentiation, and programmed cell death [32]. Its
overexpression is one of the most common alterations in
human cancers. Reports also show that the suppression of
Fig. 6 Western blotting and gelatin zymography. a The protein expression levels of the relevant downstream molecules in the Wnt/β-catenin
pathway after the treatment of U2OS cells with 50 nM oleandrin for 0, 24 and 48 h as determined by western blotting. b The semi-quantitative results of
the relevant downstream molecules in the Wnt/β-catenin pathway relative to the GAPDH protein. *P < 0.05, **P < 0.01, compared to the 0 h group.
#P < 0.05, ##P < 0.01, compared to the 24 h group. c Representative electrophoretograms of the total, nuclear and cytoplasmic β-catenin levels after
treatment with 50 nM of oleandrin for 0, 24 and 48 h using western blotting. d The semi-quantitative results of the total, nuclear and cytoplasmic
β-catenin levels based on electrophoretograms from the western blot analysis. *P < 0.05, **P < 0.01, compared to the 0 h group. #P < 0.05, ##P < 0.01,
compared to the 24 h group. (e) The MMP-2 and MMP-9 activities after treatment with 25 and 50 nM of oleandrin as detected by a gelatin zymography
assay. CP: cytoplasmic protein; NP: nuclear protein; TP: total protein
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c-myc oncogene induces cellular senescence in diverse
tumor types, including OS [31]. Survivin is an inhibitor of
the apoptosis protein and a key determinant in protecting
cells from apoptosis. It is over-expressed in most tumors,
such as OS. It displays a significant function on the devel-
opment of OS and could be taken as a prognostic factor
for OS patients [33, 34]. Cyclin D1 is a key regulator of
the G1 phase of the cell cycle [35]. It is overexpressed in
many cancers, including OS, and regulates cell prolifera-
tion through the activation of cyclin-dependent kinases
[36]. MMP-2 and MMP-9 are enzymes that are implicated
in the malignant progression of many tumor types. They
play a vital role in tumor invasion and angiogenesis [37]
and are believed to be a critical part of the invasive poten-
tial of tumor cells because of their ability to degrade type
IV collagen, a major structural component of basement
membranes [38]. In OS patients, the overexpression of
MMP-2 and MMP-9 is always observed [39].
The mRNA and protein expression of the downstream
genes of the Wnt/β-catenin pathway including c-myc,
cyclin D1, survivin, MMP-2 and MMP-9 were detected
using semi-quantitative RT-PCR and western blot assays.
As expected, both assays indicated that oleandrin, at
varying treatment lengths, could significantly downregu-
late the mRNA levels and protein expression of these
genes. We already knew that oleandrin inhibited the
migration and invasion of OS cells through influencing
the expression of MMP-2 and MMP-9. Subsequently, we
further explored the change of MMP-2 and MMP-9
activities with gelatin zymography. With the treatment
of 25 nM and 50 nM oleandrin for 24 h, the MMP-2
and MMP-9 activities were reduced. These findings
demonstrate that oleandrin not only inhibits the expres-
sion of MMP-2 and MMP-9 but also suppresses their en-
zyme activities. Therefore, based on the reports above, we
concluded that oleandrin suppressed the Wnt/β-catenin
signaling pathway by downregulating the expression of
the target genes and also inhibited the enzyme activities of
MMP-2 and MMP-9.
β-Catenin is a key molecule in the Wnt/β-catenin
signaling pathway, and its shuttling in osteosarcoma cells
between the cytoplasm and the nucleus is a common
phenomenon in terms of the activation state of the
Wnt/β-catenin pathway [40]. In the nucleus, β-catenin
interacts with TCF/LEF and triggers the transcription of
target genes. Therefore, nuclear β-catenin accumulation
is a key event in the activation of Wnt/β-catenin signal-
ing. The deregulation of the Wnt/β-catenin pathway
would result in the aberrant accumulation of β-catenin
in the nucleus, which occurs in parallel to the develop-
ment of cancer [41]. In this study, we found that the
levels of total and nuclear β-catenin were significantly
decreased in response to varying treatment lengths.
Although there was a slight decreasing trend in the
levels cytoplasmic β-catenin, no significant difference
was observed. These results indicate that oleandrin treat-
ment could effectively reduce the nuclear location of β-
catenin. To a certain degree, our findings are consistent
with those of previous studies, which have reported that
the suppression of the Wnt/β-catenin signaling pathway
would lead to the reduction of nuclear β-catenin [42].
Our results further demonstrated that oleandrin could
suppress the activity of the Wnt/β-catenin signaling
pathway.
Of course, there were limitations to this study. We
only explored the antitumor effect and underlying
mechanism of oleandrin on two human OS cell lines
in vitro. Hence, in our further studies, we will investi-
gate the antitumor effect of oleandrin in animal
models and we will study the detailed mechanisms of
the invasion inhibition and apoptosis-inducing effects
of oleandrin in vivo.
Conclusions
In conclusion, we found that oleandrin, in vitro, could
inhibit proliferation, induce apoptosis and reduce the
invasiveness of U2OS and SaOS-2 cells. The antitu-
mor activities of oleandrin on OS cells were probably
achieved by suppressing the Wnt/β-catenin signaling
pathway, which resulted in the down-regulation of
target genes and decreased the total and nuclear β-
catenin. In addition, oleandrin not only reduced
MMP-2 and MMP-9 expression but also suppressed
their activities.
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